02 June 2004
OFFICIAL OPENING MARKED BY CHARITY DONATION
The official opening today (June 2) of a new £24 million laboratory at AstraZeneca’s site in Macclesfield, Cheshire has also brought a boost for a charity.  To mark the opening of the Large Scale Laboratory (LSL) a cheque for £1,000 was presented to Marie Curie Cancer Care, one of the AstraZeneca Cheshire sites’ adopted charities for 2004. The presentation was made by Bryan Mobbs, AstraZeneca Vice President, Process Research and Development to Jane Wilkinson of Marie Curie Cancer Care.  More

24 March 2004
ASTRAZENECA OPENS NEW CENTRE FOR ADVANCED LEAD DISCOVERY
Cheshire-based facility with global impact on discovery of new and better medicines  More

17 March 2004
ASTRAZENECA ANNOUNCES LATEST PHASE OF UK £1 BILLION INVESTMENT PROGRAMME
AstraZeneca has announced two major investments in the UK with the imminent opening of major new facilities in Alderley Park, Macclesfield, Cheshire, and additional investment to support the development of its research site in Charnwood, Loughborough, Leicestershire.  More

17 March 2004
AZ listed in 'Top 100' Corporate Responsibility Survey
AstraZeneca has been listed 38th out of the 'Top 100' in one of the UK's leading Corporate Responsibility surveys. The Corporate Responsibility Index measures the various impacts that UK companies have upon society and their environment. The Index reviews companies by industry sector and this year's results have revealed that the Food and Drug Retailers have remained the leading performers. The results from the survey were featured in this week's Sunday Times - the Companies that Count Supplement. Being included in the Index illustrates that the company has taken a systematic approach to dealing with its environmental and social impacts, and recognises the need to involve key stakeholders.  More

04 November 2004
AstraZeneca recalls specific batches of Pulmicort and Briconyl pMDI in UK
AstraZeneca are recalling specific batches of its asthma medications Pulmicort (budesonide) pMDI (pressurised metered dose inhaler) and Bricanyl (terbutaline) pMDI.  This is a precautionary measure due to a small number of inhalers failing to operate or needing a higher than normal pressure to actuate.  More

09 June 2004
CRESTOR® (rosuvastatin) Important changes to prescribing Information
AstraZeneca has sent a letter to Healthcare Professionals informing them of important changes to the CRESTOR prescribing information.  More